Shots:

• The Progeria Research Foundation and Eiger reported the US FDA’s approval of Zokinvy (lonafarnib) for the treatment of HGPS or progeria and processing-deficient progeroid laminopathies
• Zokinvy reduced the incidence of mortality by 60% & increased the average survival time by 2.5 yrs. Additionally- the FDA has issued an RPD priority review voucher to Eiger
• Eiger plans to sell the PRV and will share the proceeds equally with PRF- under its supply & collaboration agreement. Zokinvy is a farnesyltransferase inhibitor that has shown a survival benefit in children with Progeria

 ­ Ref: Eiger Bio | Image: PRNewswire